Human trial / 2023
Triple-hormone-receptor agonist retatrutide for obesity — Phase 2
Triple-hormone-receptor agonist retatrutide for obesity — Phase 2 — New England Journal of Medicine / PubMed (2023), cited in PeptideAgent's Retatrutide evidence record.
Open original sourceSOURCE METADATA
What this record represents.
- Publisher
- New England Journal of Medicine / PubMed
- Evidence type
- Human trial
- Publication year
- 2023
- Source ID
- pmid-37366315
WHERE THIS IS CITED